MX2008001926A - Metodo para la prediccion de la respuesta a un tratamiento. - Google Patents

Metodo para la prediccion de la respuesta a un tratamiento.

Info

Publication number
MX2008001926A
MX2008001926A MX2008001926A MX2008001926A MX2008001926A MX 2008001926 A MX2008001926 A MX 2008001926A MX 2008001926 A MX2008001926 A MX 2008001926A MX 2008001926 A MX2008001926 A MX 2008001926A MX 2008001926 A MX2008001926 A MX 2008001926A
Authority
MX
Mexico
Prior art keywords
marker
growth factor
her2
marker gene
combination
Prior art date
Application number
MX2008001926A
Other languages
English (en)
Spanish (es)
Inventor
Joachim Moecks
Andreas Strauss
Gerhard Zugmaier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008001926(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2008001926A publication Critical patent/MX2008001926A/es

Links

Classifications

    • G01N33/57557—
    • G01N33/57515—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
MX2008001926A 2005-08-12 2006-05-24 Metodo para la prediccion de la respuesta a un tratamiento. MX2008001926A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05017663 2005-08-12
PCT/EP2006/004950 WO2007019899A2 (en) 2005-08-12 2006-05-24 Method for predicting the response to a treatment with a her dimerization inhibitor

Publications (1)

Publication Number Publication Date
MX2008001926A true MX2008001926A (es) 2008-03-24

Family

ID=35511140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001926A MX2008001926A (es) 2005-08-12 2006-05-24 Metodo para la prediccion de la respuesta a un tratamiento.

Country Status (32)

Country Link
US (2) US7700299B2 (enExample)
EP (2) EP1915460B1 (enExample)
JP (1) JP2009504142A (enExample)
KR (2) KR20080034922A (enExample)
CN (2) CN101405405A (enExample)
AR (1) AR057323A1 (enExample)
AT (2) ATE493514T1 (enExample)
AU (2) AU2006281746B2 (enExample)
BR (1) BRPI0615001A2 (enExample)
CA (1) CA2616913A1 (enExample)
CL (1) CL2010000720A1 (enExample)
CR (1) CR9686A (enExample)
CY (1) CY1111612T1 (enExample)
DE (1) DE602006019265D1 (enExample)
DK (1) DK1915460T3 (enExample)
EC (1) ECSP088171A (enExample)
ES (1) ES2356066T3 (enExample)
HR (1) HRP20110171T1 (enExample)
IL (1) IL188923A0 (enExample)
MA (1) MA31549B1 (enExample)
MX (1) MX2008001926A (enExample)
NO (1) NO20080371L (enExample)
NZ (1) NZ565270A (enExample)
PL (1) PL1915460T3 (enExample)
PT (1) PT1915460E (enExample)
RS (1) RS51859B (enExample)
RU (2) RU2408735C2 (enExample)
SI (1) SI1915460T1 (enExample)
TW (1) TW200741010A (enExample)
UA (1) UA93989C2 (enExample)
WO (1) WO2007019899A2 (enExample)
ZA (1) ZA201102688B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO2001089566A1 (en) * 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20190035967A (ko) 2004-07-22 2019-04-03 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
BRPI0518104B8 (pt) 2005-01-21 2021-05-25 Genentech Inc artigo industrializado e uso de anticorpo her2
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
JP2010520225A (ja) 2007-03-02 2010-06-10 ジェネンテック， インコーポレイテッド 低ｈｅｒ３発現に基づくｈｅｒ二量化インヒビターに対する応答を予測する方法
JP5433189B2 (ja) * 2007-09-28 2014-03-05 承一 尾崎 Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
AU2008341050B2 (en) * 2007-12-26 2013-10-24 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
JP2011517555A (ja) * 2008-03-14 2011-06-16 ジェネンテック， インコーポレイテッド 薬剤耐性に関連する遺伝的変異
ES2430590T3 (es) * 2008-05-14 2013-11-21 Genomic Health, Inc. Predictores de la respuesta de pacientes al tratamiento con inhibidores del receptor del EGF
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
EP2387717B1 (en) * 2009-01-15 2014-12-10 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-2 expression
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011132182A1 (en) * 2010-04-18 2011-10-27 Yeda Research And Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
CA2823397C (en) * 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9828635B2 (en) * 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
PL4234033T3 (pl) 2011-10-14 2025-04-28 F. Hoffmann-La Roche Ag Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2
AU2012363873B2 (en) 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
CN104349773A (zh) 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
EP3800204A1 (en) 2013-04-16 2021-04-07 F. Hoffmann-La Roche AG Pertuzumab variants and evaluation thereof
WO2015017529A2 (en) * 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
EP2876442A1 (en) * 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
JP2017513901A (ja) 2014-04-25 2017-06-01 ジェネンテック， インコーポレイテッド トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
JP2017528430A (ja) 2014-07-17 2017-09-28 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定
PT3302551T (pt) 2015-05-30 2024-08-21 H Hoffnabb La Roche Ag Métodos de tratamento do cancro da mama metastático positivo para her2 não tratado previamente
CA2992925A1 (en) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN105403704A (zh) * 2015-12-31 2016-03-16 苏州市博纳泰科生物技术有限公司 Her-2的荧光免疫层析检测方法及试剂盒
EP3534948A1 (en) 2016-11-04 2019-09-11 Genentech, Inc. Treatment of her2-positive breast cancer
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
CR20190376A (es) 2017-01-17 2019-11-20 Genentech Inc Formulaciones de anticuerpos de her2 subcutáneas
KR20190096384A (ko) 2017-03-02 2019-08-19 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
KR20190140952A (ko) 2017-04-24 2019-12-20 제넨테크, 인크. 막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이
MX420940B (es) 2018-05-25 2025-02-10 Bioneer Corp Oligonucleótido bicatenario específico del gen de anfirregulina y composición para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
KR20250057808A (ko) * 2022-08-09 2025-04-29 헬리제닉스 아이엔씨. 유전자 변이의 임상적 관련성을 평가하는 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
KR100628846B1 (ko) 1996-10-18 2006-09-29 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
NZ516830A (en) 1999-06-25 2004-07-30 Genentech Inc Humanized anti-ErbB2 antibodies conjugated with a cytotoxic or chemotherapeutic agent for treating cancer
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
ES2616800T3 (es) * 2002-03-13 2017-06-14 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
EP2263691B1 (en) * 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
ES2246191T1 (es) * 2002-12-11 2006-02-16 Ventana Medical Systems, Inc. Metodo para predecir la respuesta a la terapia dirigida a her2.
AU2004211955B2 (en) 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
BRPI0408928A (pt) 2003-04-01 2006-09-12 Monogram Biosciences Inc métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
CA2527680A1 (en) 2003-05-30 2005-06-02 Astrazeneca Uk Limited Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
JP2007512807A (ja) 2003-10-28 2007-05-24 バイエル ヘルスケア アーゲー 悪性腫瘍の処置に対する応答予測のための方法および組成物
TWM256978U (en) * 2004-04-02 2005-02-11 Nventec Appliances Corp Electronic device
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
RU2300111C2 (ru) * 2005-06-15 2007-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ прогнозирования течения заболевания раком молочной железы

Also Published As

Publication number Publication date
US20070037228A1 (en) 2007-02-15
CN101705287A (zh) 2010-05-12
RU2008108907A (ru) 2009-09-20
PT1915460E (pt) 2011-03-17
EP1915460A2 (en) 2008-04-30
RS51859B (sr) 2012-02-29
AU2006281746B2 (en) 2011-06-23
AU2006281746A1 (en) 2007-02-22
ZA201102688B (en) 2012-01-25
NO20080371L (no) 2008-05-09
JP2009504142A (ja) 2009-02-05
ATE493514T1 (de) 2011-01-15
KR20080034922A (ko) 2008-04-22
AR057323A1 (es) 2007-11-28
RU2408735C2 (ru) 2011-01-10
HRP20110171T1 (hr) 2011-04-30
WO2007019899A8 (en) 2010-08-05
WO2007019899A2 (en) 2007-02-22
UA93989C2 (ru) 2011-03-25
CA2616913A1 (en) 2007-02-22
MA31549B1 (fr) 2010-08-02
EP2196547B1 (en) 2011-12-28
PL1915460T3 (pl) 2011-05-31
CL2010000720A1 (es) 2010-12-03
BRPI0615001A2 (pt) 2011-04-26
AU2011202339A1 (en) 2011-06-09
CN101405405A (zh) 2009-04-08
WO2007019899A3 (en) 2007-04-05
ATE539171T1 (de) 2012-01-15
DK1915460T3 (da) 2011-01-31
IL188923A0 (en) 2008-08-07
US7700299B2 (en) 2010-04-20
SI1915460T1 (sl) 2011-04-29
NZ565270A (en) 2011-05-27
DE602006019265D1 (de) 2011-02-10
EP2196547A1 (en) 2010-06-16
CY1111612T1 (el) 2015-10-07
RU2010115252A (ru) 2011-10-27
ECSP088171A (es) 2008-03-26
TW200741010A (en) 2007-11-01
US20100112603A1 (en) 2010-05-06
CR9686A (es) 2008-02-20
ES2356066T3 (es) 2011-04-04
KR20110074921A (ko) 2011-07-04
EP1915460B1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
AU2006281746B2 (en) Method for predicting the response to a treatment
Revillion et al. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis
US8129114B2 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
MX2007009963A (es) Mutaciones del receptor del factor de crecimiento epidermico.
WO2010085845A1 (en) Cancer therapy and/or diagnosis
KR20110018930A (ko) 암 치료에서 예후적 및 예견적 마커의 확인 및 용도
WO2009150127A1 (en) A method for predicting responsiveness to a treatment with an anti-her2 antibody
Koutras et al. The epidermal growth factor receptor family in breast cancer
US20200232039A1 (en) Adm2 gene marker for diagnosis or prognosis prediction of thyroid cancer and uses thereof
AU2011222867B2 (en) Method for selecting patients for treatment with an EGFR inhibitor
KR20070103001A (ko) 암치료에서 예후적 및 예견적 마커의 확인 및 용도
CA2768475A1 (en) Methods and kits used in assessing cancer risk
HK1139711A (en) Method for predicting the response to a treatment

Legal Events

Date Code Title Description
FG Grant or registration